Recursion Pharmaceuticals（Recursion 制药公司）正计划裁员约 20%，作为精简运营和降低成本计划的一部分。此次裁员将产生约 1100 万美元的相关费用。
预计 2025 年现金消耗将低于 4.5 亿美元，2026 年低于 3.9 亿美元。该公司有望在 2026 年底前从合作伙伴处获得超过 1 亿美元的现金流入。截至 2025 年 6 月 30 日，Recursion 的现金状况预计将超过 5 亿美元。目前预计现金跑道将延长至 2027 年第四季度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.